172 related articles for article (PubMed ID: 33126945)
1. Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini.
Vambe D; Kay AW; Furin J; Howard AA; Dlamini T; Dlamini N; Shabangu A; Hassen F; Masuku S; Maha O; Wawa C; Mafukidze A; Altaye K; Sikhondze W; Gwitima T; Keus K; Simelane T; Kerschberger B
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1095-1102. PubMed ID: 33126945
[No Abstract] [Full Text] [Related]
2. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
[TBL] [Abstract][Full Text] [Related]
3. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
Cox V; Brigden G; Crespo RH; Lessem E; Lynch S; Rich ML; Waning B; Furin J
Int J Tuberc Lung Dis; 2018 Apr; 22(4):407-412. PubMed ID: 29562988
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
Kempker RR; Mikiashvili L; Zhao Y; Benkeser D; Barbakadze K; Bablishvili N; Avaliani Z; Peloquin CA; Blumberg HM; Kipiani M
Clin Infect Dis; 2020 Dec; 71(9):2336-2344. PubMed ID: 31712809
[TBL] [Abstract][Full Text] [Related]
5. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Sarin R; Vohra V; Singla N; Singla R; Puri MM; Munjal SK; Khalid UK; Myneedu VP; Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):184-188. PubMed ID: 30878066
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
Battaglia S; Spitaleri A; Cabibbe AM; Meehan CJ; Utpatel C; Ismail N; Tahseen S; Skrahina A; Alikhanova N; Mostofa Kamal SM; Barbova A; Niemann S; Groenheit R; Dean AS; Zignol M; Rigouts L; Cirillo DM
J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32907992
[TBL] [Abstract][Full Text] [Related]
7. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid.
Lee HH; Jo KW; Yim JJ; Jeon D; Kang H; Shim TS
Int J Infect Dis; 2020 Sep; 98():478-485. PubMed ID: 32640367
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Huerga H; Khan U; Bastard M; Mitnick CD; Lachenal N; Khan PY; Seung KJ; Melikyan N; Ahmed S; Rich ML; Varaine F; Osso E; Rashitov M; Salahuddin N; Salia G; Sánchez E; Serobyan A; Rafi Siddiqui M; Grium Tefera D; Vetushko D; Yeghiazaryan L; Holtzman D; Islam S; Kumsa A; Jacques Leblanc G; Leonovich O; Mamsa S; Manzur-Ul-Alam M; Myint Z; Padayachee S; Franke MF; Hewison C
Clin Infect Dis; 2022 Oct; 75(8):1307-1314. PubMed ID: 35243494
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study.
Byun JH; Park JA; Kang HR; Shin JY; Lee EK
Clin Drug Investig; 2016 Nov; 36(11):957-968. PubMed ID: 27465204
[TBL] [Abstract][Full Text] [Related]
10. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
[TBL] [Abstract][Full Text] [Related]
12. Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea.
Kang H; Jo KW; Jeon D; Yim JJ; Shim TS
Respir Med; 2020 Jun; 167():105956. PubMed ID: 32421540
[TBL] [Abstract][Full Text] [Related]
13. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
[TBL] [Abstract][Full Text] [Related]
14. Early mortality during rifampicin-resistant TB treatment.
Mohr-Holland E; Daniels J; Reuter A; Rodriguez CA; Mitnick C; Kock Y; Cox V; Furin J; Cox H
Int J Tuberc Lung Dis; 2022 Feb; 26(2):150-157. PubMed ID: 35086627
[TBL] [Abstract][Full Text] [Related]
15. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
Nair P; Hasan T; Zaw KK; Allamuratova S; Ismailov A; Mendonca P; Bekbaev Z; Parpieva N; Singh J; Sitali N; Bermudez-Aza E; Sinha A
Int J Tuberc Lung Dis; 2022 Jul; 26(7):658-663. PubMed ID: 35768925
[TBL] [Abstract][Full Text] [Related]
16. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
17. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
[TBL] [Abstract][Full Text] [Related]
19. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
[TBL] [Abstract][Full Text] [Related]
20. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
Li Y; Sun F; Zhang W
Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
